| Acadia Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders. Co.'s portfolio of products includes its drug, NUPLAZID (pimavanserin), which has been approved by the U.S. Food and Drug Administration for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist preferentially targeting 5-HT2A receptors. In addition to PD Psychosis, Co.'s pipeline includes multiple product opportunities being explored in clinical development across several CNS disorders. We show 39 historical shares outstanding datapoints in our coverage of ACAD's shares outstanding history.|
Understanding the changing numbers of ACAD shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ACAD versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ACAD by allowing them to research ACAD shares outstanding history
as well as any other stock in our coverage universe.